Your browser doesn't support javascript.
Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.
Atyeo, Caroline; Fischinger, Stephanie; Zohar, Tomer; Slein, Matthew D; Burke, John; Loos, Carolin; McCulloch, Denise J; Newman, Kira L; Wolf, Caitlin; Yu, Jingyou; Shuey, Kiel; Feldman, Jared; Hauser, Blake Marie; Caradonna, Tim; Schmidt, Aaron G; Suscovich, Todd J; Linde, Caitlyn; Cai, Yongfei; Barouch, Dan; Ryan, Edward T; Charles, Richelle C; Lauffenburger, Douglas; Chu, Helen; Alter, Galit.
  • Atyeo C; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; PhD Program in Virology, Division of Medical Sciences, Harvard University, Boston, MA, USA.
  • Fischinger S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; PhD Program in Immunology and Virology, University of Duisburg-Essen, Essen, Germany.
  • Zohar T; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Slein MD; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Burke J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Loos C; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • McCulloch DJ; Department of Medicine, University of Washington, Seattle, WA, USA.
  • Newman KL; Department of Medicine, University of Washington, Seattle, WA, USA.
  • Wolf C; Department of Medicine, University of Washington, Seattle, WA, USA.
  • Yu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Shuey K; Department of Medicine, University of Washington, Seattle, WA, USA.
  • Feldman J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Hauser BM; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Caradonna T; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Schmidt AG; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Suscovich TJ; SeromYx Systems, Cambridge, MA, USA.
  • Linde C; SeromYx Systems, Cambridge, MA, USA.
  • Cai Y; Division of Molecular Medicine, Boston Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Barouch D; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Ryan ET; Infectious Disease Division, Massachusetts General Hospital, Boston, MA, USA.
  • Charles RC; Infectious Disease Division, Massachusetts General Hospital, Boston, MA, USA.
  • Lauffenburger D; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Chu H; Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: helenchu@uw.edu.
  • Alter G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA. Electronic address: galter@partners.org.
Immunity ; 53(3): 524-532.e4, 2020 09 15.
Article in English | MEDLINE | ID: covidwho-709168
ABSTRACT
As SARS-CoV-2 infections and death counts continue to rise, it remains unclear why some individuals recover from infection, whereas others rapidly progress and die. Although the immunological mechanisms that underlie different clinical trajectories remain poorly defined, pathogen-specific antibodies often point to immunological mechanisms of protection. Here, we profiled SARS-CoV-2-specific humoral responses in a cohort of 22 hospitalized individuals. Despite inter-individual heterogeneity, distinct antibody signatures resolved individuals with different outcomes. Although no differences in SARS-CoV-2-specific IgG levels were observed, spike-specific humoral responses were enriched among convalescent individuals, whereas functional antibody responses to the nucleocapsid were elevated in deceased individuals. Furthermore, this enriched immunodominant spike-specific antibody profile in convalescents was confirmed in a larger validation cohort. These results demonstrate that early antigen-specific and qualitative features of SARS-CoV-2-specific antibodies point to differences in disease trajectory, highlighting the potential importance of functional antigen-specific humoral immunity to guide patient care and vaccine development.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Nucleocapsid Proteins / Spike Glycoprotein, Coronavirus / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study / Qualitative research Topics: Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Immunity Journal subject: Allergy and Immunology Year: 2020 Document Type: Article Affiliation country: J.immuni.2020.07.020

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Nucleocapsid Proteins / Spike Glycoprotein, Coronavirus / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study / Qualitative research Topics: Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Immunity Journal subject: Allergy and Immunology Year: 2020 Document Type: Article Affiliation country: J.immuni.2020.07.020